Participating Faculty: Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

, , , ,
Supplements and Featured Publications, Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Anal, Volume 20, Issue 13 Suppl

This supplement to The American Journal of Managed Care describes the results of a post hoc analysis designed to evaluate attainment of diabetes-related quality measures with canagliflozin 100 mg, canagliflozin 300 mg, and sitagliptin 100 mg in patients with type 2 diabetes mellitus. This information may be relevant to stakeholders increasingly focused on quality measures and population health management, such as payers, healthcare delivery organizations, and clinicians.This supplement was supported by Janssen Pharmaceuticals, Inc.

This analysis was funded by Janssen Scientific Affairs, LLC. Editorial support was provided by Bilge Yoruk, PhD, of Excerpta Medica, and was funded by Janssen Scientific Affairs, LLC.

Faculty

Robert A. Bailey, MD

Director

Health Economics and Outcomes Research

Janssen Scientific Affairs, LLC

Raritan, New Jersey

Lawrence Blonde, MD

Director

Ochsner Diabetes Clinical Research Unit

Department of Endocrinology, Diabetes, and Metabolic Diseases

Ochsner Medical Center

New Orleans, Louisiana

Gary E. Meininger, MD

Vice President, Franchise Medical Leader

Janssen Research and Development, LLC

Raritan, New Jersey

Marcia F.T. Rupnow, PhD

Senior Director

Health Economics and Outcomes Research

Janssen Scientific Affairs, LLC

Raritan, New Jersey

Ujjwala Vijapurkar, PhD

Associate Director

Janssen Research and Development, LLC

Raritan, New Jersey

Faculty Disclosures

These faculty report relationships with the following organizations:

Robert A. Bailey, MD

Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership: Johnson & Johnson

Lawrence Blonde, MD

Grants: Eli Lilly and Company, Novo Nordisk, and sanofi-aventis

Honoraria: AstraZeneca, Janssen Pharmaceuticals, Inc, Merck & Co, Inc, Novo Nordisk, Quest Diagnostics, and sanofi-aventis

Gary E. Meininger, MD

Employment: Janssen Research and Development, LLC

Stock ownership: Johnson & Johnson

Marcia F. T. Rupnow, PhD

Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership: Johnson & Johnson

Ujjwala Vijapurkar, PhD

Employment: Janssen Research and Development, LLC

Stock ownership: Johnson & Johnson

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.